Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.

Mikael Simons, Frank Schwärzler, Dieter Lütjohann, Klaus von Bergmann, Konrad Beyreuther, Johannes Dichgans, Henning Wormstall, Tobias Hartmann, Jörg B Schulz

Journal: Annals of neurology 2002;52(3):346-50

PMID: 12205648

Full Text on Wiley View on PubMed

Abstract

In a randomized, placebo-controlled, double-blind study, we investigated whether statins alter cholesterol metabolites and reduce Abeta levels in the cerebrospinal fluid of 44 patients with Alzheimer's disease. Individuals were given up to 80mg simvastatin daily or placebo for 26 weeks. Overall, simvastatin did not significantly alter cerebrospinal fluid levels of Abeta40 and Abeta42. In post hoc analysis, simvastatin significantly decreased Abeta40 levels in the cerebrospinal fluid of patients with mild Alzheimer's disease. The reduction of Abeta40 correlated with the reduction of 24S-hydroxycholesterol. These changes were not observed in more severely affected patients.

Address: Department of Neurology, University of Tübingen, Germany.

DOI: 10.1002/ana.10292

Link outs

Free resources

Medical:

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://onlinelibrary.wiley.com/resolve/openurl?ge...

MeSH Terms: Aged, Alzheimer Disease, Amyloid beta-Peptides, Anticholesteremic Agents, Cholesterol, Double-Blind Method, Female, Humans, Male, Mental Status Schedule, Middle Aged, Peptide Fragments, Placebos, Simvastatin